Clinical trial · Observational
A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer
NCT06323265CI-TRIAL-00075466unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess efficacy and safety of patients who receive Adebrelimab combined with chemotherapy±chest radiotherapy as first-line treatment of extensive stage small cell lung cancer in the real world.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extensive Stage Small Cell Lung Cancer | Lung Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adebrelimab + chemotherapy | Drug | — | UNRESOLVED |
| ±chest radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Experimental
- interventionNames
- Drug: Adebrelimab + chemotherapy
- Radiation: ±chest radiotherapy
Primary outcomes (1)
- measure
- Progression free survival (PFS)
- timeFrame
- evaluated in 24 months since the treatment began
- description
- Baseline to measured date of progression or death from any cause
Secondary outcomes (5)
- measure
- Objective response rate (ORR)
- timeFrame
- tumor assessment every 6 weeks since the treatment began，up to 24 months
- description
- Baseline to measured stable disease
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age:≥18 years old; 2. Patients with extensive stage small cell lung cancer confirmed by histopathology; 3. Normal function of major organs; 4. Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up. Exclusion Criteria: 1. Patients with drug allergy sufferers; 2. Serious and uncontrolled organic lesions or infections, such as decompensated heart, lung, kidney failure, etc; 3. History of psychiatric drugs abuse and can't quit or patients with mental disorders; 4. The researchers think inappropriate.
References
Publications (0)
Data not yet available
No reference posted for this study.